INS and diabetes mellitus: Rapamycin, an autophagy activator inhibiting mTORC1, can also worsen the diagnosis by leading to an increase in insulin resistance and reducing β-cell mass and function, adding reasons for caution while considering autophagy activation as a therapeutic goal in diabetes [128].